- Home
- GPCR
as 11-15-2024 4:00pm EST
Stocks
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.8B | IPO Year: | 2023 |
| Target Price: | $86.80 | AVG Volume (30 days): | 677.5K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.61 - $66.38 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Structure Therapeutics Inc. News
GPCR Breaking Stock News: Dive into GPCR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
GlobeNewswire
4 days ago
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
4 days ago
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
GlobeNewswire
17 days ago
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
BioPharma Dive
24 days ago
GPCR drugmaker Septerna amasses $288M in IPO
Insider Monkey
a month ago
Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes
Zacks
a month ago
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
Investor's Business Daily
a month ago
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Compare GPCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GPCR Structure Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.